[酰基尿激酶及尿激酶组合在体外的纤溶和纤维蛋白原溶解作用]

[Fibrinolytic and fibrinogenolytic effects of acyl urokinase and urokinase combinations in vitro].

作者信息

Mukhametova L I, Aĭsina R B, Varfolomeev S D

出版信息

Bioorg Khim. 2006 Jul-Aug;32(4):384-90. doi: 10.1134/s1068162006040042.

DOI:10.1134/s1068162006040042

Abstract

The in vitro thrombolytic and side effects of double-strand urokinase-type plasminogen activator (tcu-PA), p-guanidinobenzoyl tcu-PA (GB-tcu-PA), and their combinations were compared. The reversible blocking of the active site stabilizes GB-tcu-PA in human plasma and results in longer thrombolysis and lesser side effects than those of tcu-PA. However, the acylated activator displays a marked lag period of thrombolytic action. GB-tcu-PA and tcu-PA combinations (molar ratios 4 : 1 and 1 : 1) induce a prolonged and effective thrombolysis without the initial lag period at a low level of plasminogen, fibrinogen, and alpha2-antiplasmin depletion in the plasma surrounding the clot.

摘要

比较了双链尿激酶型纤溶酶原激活剂（tcu-PA）、对胍基苯甲酰tcu-PA（GB-tcu-PA）及其组合的体外溶栓作用和副作用。活性位点的可逆性阻断使GB-tcu-PA在人血浆中更稳定，与tcu-PA相比，其溶栓时间更长，副作用更小。然而，酰化激活剂表现出明显的溶栓作用延迟期。GB-tcu-PA与tcu-PA的组合（摩尔比4:1和1:1）在纤溶酶原、纤维蛋白原和α2-抗纤溶酶水平较低的情况下，能在不出现初始延迟期的情况下诱导延长且有效的溶栓作用，同时在血凝块周围血浆中的消耗较少。

相似文献

1

[Fibrinolytic and fibrinogenolytic effects of acyl urokinase and urokinase combinations in vitro].[酰基尿激酶及尿激酶组合在体外的纤溶和纤维蛋白原溶解作用]

Bioorg Khim. 2006 Jul-Aug;32(4):384-90. doi: 10.1134/s1068162006040042.

2

Effect of standard heparin and a low molecular weight heparin on thrombolytic and fibrinolytic activity of single-chain urokinase plasminogen activator in vitro.标准肝素和低分子量肝素对单链尿激酶型纤溶酶原激活剂体外溶栓和纤溶活性的影响。

Thromb Haemost. 1989 Nov 24;62(3):923-6.

3

Comparison of the relative fibrinogenolytic, fibrinolytic and thrombolytic properties of tissue plasminogen activator and urokinase in vitro.组织型纤溶酶原激活剂与尿激酶在体外的相对纤维蛋白溶解、纤溶及溶栓特性比较

Thromb Haemost. 1981 Jun 30;45(3):225-9.

4

The nature of synergy between tissue-type and single chain urokinase-type plasminogen activators.组织型与单链尿激酶型纤溶酶原激活剂之间协同作用的本质。

Thromb Haemost. 1989 Nov 24;62(3):909-16.

5

Comparison of thrombolytic, fibrinolytic, and fibrinogenolytic properties of tissue plasminogen activator, streptokinase, single-chain urokinase, high molecular weight and low molecular weight urokinase in human plasma in vitro.组织型纤溶酶原激活剂、链激酶、单链尿激酶、高分子量和低分子量尿激酶在人血浆中的溶栓、纤维蛋白溶解和纤维蛋白原溶解特性的体外比较

Fundam Clin Pharmacol. 1988;2(6):509-23. doi: 10.1111/j.1472-8206.1988.tb00652.x.

6

Synergy of in vitro thrombolytic action of combinations of recombinant staphylokinase and single-chain urokinase-type plasminogen activator.重组葡萄球菌激酶与单链尿激酶型纤溶酶原激活剂组合的体外溶栓作用协同性。

Biochemistry (Mosc). 2003 Nov;68(11):1252-60. doi: 10.1023/b:biry.0000009141.17272.6c.

7

Absence of synergism between tissue-type plasminogen activator (t-PA), single-chain urokinase-type plasminogen activator (scu-PA) and urokinase on clot lysis in a plasma milieu in vitro.组织型纤溶酶原激活剂（t-PA）、单链尿激酶型纤溶酶原激活剂（scu-PA）和尿激酶在体外血浆环境中对血凝块溶解不存在协同作用。

Thromb Haemost. 1986 Aug 20;56(1):35-9.

8

Effect of fibrin-targeting on clot lysis with urokinase-type plasminogen activator.纤维蛋白靶向对尿激酶型纤溶酶原激活剂溶栓作用的影响。

Thromb Res. 1990 Feb 1;57(3):333-42. doi: 10.1016/0049-3848(90)90249-c.

9

Pharmacokinetics and pharmacodynamics of saruplase, an unglycosylated single-chain urokinase-type plasminogen activator, in patients with acute myocardial infarction.

Thromb Haemost. 1994 Nov;72(5):740-4.

10

Potentiation by Lys-plasminogen of clot lysis by single or two chain urokinase-type plasminogen activator or tissue-type plasminogen activator.赖氨酸纤溶酶原对单链或双链尿激酶型纤溶酶原激活剂或组织型纤溶酶原激活剂所致血凝块溶解的增强作用。

Thromb Haemost. 1989 Jun 30;61(3):502-6.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

文档翻译

学术文献翻译模型，支持多种主流文档格式。